High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
Authors
Keywords
-
Journal
Diagnostic Pathology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-11
DOI
10.1186/s13000-020-00971-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers
- (2019) Yanjun Hou et al. HUMAN PATHOLOGY
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
- (2019) Cretella et al. Cancers
- The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
- (2018) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
- (2018) Elisa Gobbini et al. EUROPEAN JOURNAL OF CANCER
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer
- (2018) Zhengbo Song et al. LUNG CANCER
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAGI2 is an independent predictor of biochemical recurrence in prostate cancer
- (2018) Stephanie N. David et al. PROSTATE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast
- (2018) Semir Vranic et al. Clinical Breast Cancer
- Lung Cancer with a High Tumor Mutational Burden
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
- (2018) Michael Offin et al. CLINICAL CANCER RESEARCH
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel
- (2017) Kazuya Takamochi et al. LUNG CANCER
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications
- (2017) Yu-Pei Chen et al. Theranostics
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma
- (2016) Jeffery Goldstein et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
- (2016) R. M. Chabanon et al. CLINICAL CANCER RESEARCH
- MAGI-2 in prostate cancer: an immunohistochemical study
- (2016) Jeffery Goldstein et al. HUMAN PATHOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
- (2016) Tavi Nathanson et al. Cancer Immunology Research
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer
- (2014) Reza Mahdian et al. MOLECULAR BIOLOGY REPORTS
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAGI-2 scaffold protein is critical for kidney barrier function
- (2014) M. D. Balbas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
- (2014) Felix Dietlein et al. TRENDS IN GENETICS
- DNA Mismatch Repair Deficiency in Breast Carcinoma
- (2012) Yong H. Wen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Role of microsatellite instability in the management of colorectal cancers
- (2012) Bruno Buecher et al. DIGESTIVE AND LIVER DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now